Precision Biosciences ( (DTIL) ) has released its Q3 earnings. Here is a breakdown of the information Precision Biosciences presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Precision BioSciences, Inc. is a clinical-stage gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet needs. The company recently announced its third-quarter 2025 financial results, highlighting significant progress in its gene editing pipeline, particularly with its PBGENE-HBV and PBGENE-DMD programs.
In the third quarter, Precision BioSciences showcased promising Phase 1 data for its PBGENE-HBV program, aimed at curing chronic hepatitis B, and commenced dosing in Cohort 3 of the ELIMINATE-B trial. The company also anticipates filing an investigational new drug application for PBGENE-DMD by the end of 2025, with clinical trials expected to begin in 2026. Financially, the company reported a net loss of $21.8 million, with cash reserves projected to support operations into the second half of 2027.
Key financial metrics include a decrease in total revenue to less than $0.1 million compared to the previous year, primarily due to reduced billable efforts under the Novartis Agreement. Research and development expenses slightly increased to $13.4 million, driven by advancements in the PBGENE-DMD program, while general and administrative expenses decreased to $7.3 million. The company also received an $8 million milestone payment from its partner, Imugene.
Looking ahead, Precision BioSciences is focused on advancing its clinical programs, with expectations of achieving significant milestones for PBGENE-HBV and PBGENE-DMD. The company remains optimistic about the potential of its ARCUS platform to deliver transformative therapies for genetic and infectious diseases.